Literature DB >> 12100034

Conserved CDR 3 region of T cell receptor BV gene in lymphocytes from bronchoalveolar lavage fluid of patients with idiopathic pulmonary fibrosis.

N Shimizudani1, H Murata, H Keino, S Kojo, H Nakamura, Y Morishima, T Sakamoto, M Ohtsuka, K Sekisawa, M Sumida, T Sumida, T Matsuoka.   

Abstract

Idiopathic pulmonary fibrosis (IPF) is an inflammatory lung disease characterized by the accumulation of inflammatory cells and deposition of collagen, resulting in lung remodelling. High numbers of T cells are present in bronchoalveolar lavage fluid (BALF) of IPF patients, although the characteristics of these cells are yet to be determined. To elucidate the pathogenic mechanisms of IPF, we analysed the T cell receptor (TCR) of BALF lymphocytes in three patients with IPF and three healthy subjects as control. TCR repertoire of BALF lymphocytes and T cell clonality were examined by family PCR and Southern blot analysis, and single-strand conformation polymorphism (SSCP), respectively. We observed that the TCR repertoire in the lung was heterogeneous, both in the control subjects and three patients with IPF. SSCP analysis demonstrated an increase in the number of accumulated T cell clones in BALF of two of the three patients, but not in the healthy subject. Furthermore, junctional sequence analysis showed the presence of conserved amino acid motifs (ETGRSG, LAxG, QGQ, GxQP, GRxG, VAR, PGT, GTI, GGT, TGR, LxLxQ, SGQ) in the TCR-CDR 3 region of BAL lymphocytes in patients with IPF, whereas only two amino acid motifs (VTTG, GGE) were found in the control. Our findings suggest that T cells in BALF of patients with IPF expand oligoclonally in the lung, suggesting antigen stimulation of these cells.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12100034      PMCID: PMC1906425          DOI: 10.1046/j.1365-2249.2002.01871.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  30 in total

1.  Elevation of antibodies to cytomegalovirus and other herpes viruses in pulmonary fibrosis.

Authors:  M Yonemaru; I Kasuga; H Kusumoto; A Kunisawa; H Kiyokawa; S Kuwabara; Y Ichinose; K Toyama
Journal:  Eur Respir J       Date:  1997-09       Impact factor: 16.671

Review 2.  Idiopathic pulmonary fibrosis: clinical relevance of pathologic classification.

Authors:  A L Katzenstein; J L Myers
Journal:  Am J Respir Crit Care Med       Date:  1998-04       Impact factor: 21.405

3.  Detection of adenovirus E1A DNA in pulmonary fibrosis using nested polymerase chain reaction.

Authors:  K Kuwano; Y Nomoto; R Kunitake; N Hagimoto; T Matsuba; Y Nakanishi; N Hara
Journal:  Eur Respir J       Date:  1997-07       Impact factor: 16.671

4.  Oligoclonal V gene usage by T lymphocytes in bronchoalveolar lavage fluid from sarcoidosis patients.

Authors:  C M Jones; R A Lake; J B Wijeyekoon; D M Mitchell; R M du Bois; R E O'Hehir
Journal:  Am J Respir Cell Mol Biol       Date:  1996-05       Impact factor: 6.914

5.  TCR V beta families in T cell clones from sarcoid lung parenchyma, BAL, and blood.

Authors:  G Zissel; I Bäumer; B Fleischer; M Schlaak; J Müller-Quernheim
Journal:  Am J Respir Crit Care Med       Date:  1997-11       Impact factor: 21.405

6.  Determination of gamma/delta and other T-lymphocyte subsets in bronchoalveolar lavage fluid and peripheral blood from patients with sarcoidosis and idiopathic fibrosis of the lung.

Authors:  R Gruber; A Pforte; B Beer; G Riethmüller
Journal:  APMIS       Date:  1996-03       Impact factor: 3.205

7.  Cryptogenic fibrosing alveolitis: lack of association with Epstein-Barr virus infection.

Authors:  A Wangoo; R J Shaw; T C Diss; P J Farrell; R M du Bois; A G Nicholson
Journal:  Thorax       Date:  1997-10       Impact factor: 9.139

8.  Prognostic significance of histopathologic subsets in idiopathic pulmonary fibrosis.

Authors:  J A Bjoraker; J H Ryu; M K Edwin; J L Myers; H D Tazelaar; D R Schroeder; K P Offord
Journal:  Am J Respir Crit Care Med       Date:  1998-01       Impact factor: 21.405

9.  T cell receptor (TCR) Vbeta gene usage in bronchoalveolar lavage and peripheral blood T cells from asthmatic and normal subjects.

Authors:  E Hodges; J Dasmahapatra; J L Smith; C T Quin; S Lanham; M T Krishna; S T Holgate; A J Frew
Journal:  Clin Exp Immunol       Date:  1998-06       Impact factor: 4.330

Review 10.  Idiopathic pulmonary fibrosis: current concepts.

Authors:  J H Ryu; T V Colby; T E Hartman
Journal:  Mayo Clin Proc       Date:  1998-11       Impact factor: 7.616

View more
  4 in total

Review 1.  Idiopathic pulmonary fibrosis-an epidemiological and pathological review.

Authors:  Andrea T Borchers; Christopher Chang; Carl L Keen; M Eric Gershwin
Journal:  Clin Rev Allergy Immunol       Date:  2011-04       Impact factor: 8.667

2.  CD28 down-regulation on circulating CD4 T-cells is associated with poor prognoses of patients with idiopathic pulmonary fibrosis.

Authors:  Syed R Gilani; Louis J Vuga; Kathleen O Lindell; Kevin F Gibson; Jianmin Xue; Naftali Kaminski; Vincent G Valentine; Emily K Lindsay; M Patricia George; Chad Steele; Steven R Duncan
Journal:  PLoS One       Date:  2010-01-29       Impact factor: 3.240

3.  Early interstitial lung disease in familial pulmonary fibrosis.

Authors:  Ivan O Rosas; Ping Ren; Nilo A Avila; Catherine K Chow; Teri J Franks; William D Travis; J Philip McCoy; Rose M May; Hai-Ping Wu; Dao M Nguyen; Mauricio Arcos-Burgos; Sandra D MacDonald; Bernadette R Gochuico
Journal:  Am J Respir Crit Care Med       Date:  2007-07-19       Impact factor: 21.405

4.  The HLA class II Allele DRB1*1501 is over-represented in patients with idiopathic pulmonary fibrosis.

Authors:  Jianmin Xue; Bernadette R Gochuico; Ahmad Samer Alawad; Carol A Feghali-Bostwick; Imre Noth; Steven D Nathan; Glenn D Rosen; Ivan O Rosas; Sanja Dacic; Iclal Ocak; Carl R Fuhrman; Karen T Cuenco; Mary A Smith; Susan S Jacobs; Adriana Zeevi; Penelope A Morel; Joseph M Pilewski; Vincent G Valentine; Kevin F Gibson; Naftali Kaminski; Frank C Sciurba; Yingze Zhang; Steven R Duncan
Journal:  PLoS One       Date:  2011-02-23       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.